Lancet oncol:乐伐替尼联合派姆单抗治疗转移性肾细胞癌的疗效可期!

2021-06-16 MedSci原创 MedSci原创

乐伐替尼联合派姆单抗在既往接受过ICI治疗的转移性RCC患者中表现出了令人鼓舞的抗肿瘤活性和可控的安全性,或可成为这类患者的新选择

尽管转移性肾细胞癌 (RCC) 的一线治疗取得了进展,但在使用免疫检查点抑制剂 (ICI) 治疗期间或之后针对疾病进展的治疗选择仍寥寥无几。已有数据表明,派姆单抗和乐伐替尼作为单一疗法在RCC中有效,但这个两个药物联合治疗RCC患者的疗效尚不明确。

该研究旨在评估乐伐替尼联合派姆单抗用于RCC患者的疗效的安全性。

本文报告了一项评估 乐伐替尼联合派姆单抗用于实体肿瘤患者的1b/2期开放性研究中转移性RCC队列的研究结果。受试患者每日口服20 mg 乐伐替尼,每3周静滴一次200 mg 派姆单抗,直到病情进展、出现不可耐受的毒性或撤出研究。并根据既往治疗情况进行亚组分析:初治、ICI初治和既往采用ICI治疗过的患者。主要终点是24周时的客观缓解率。

2015年7月21日-2019年10月16日,共招募了145位患者,其中2位是非透明细胞RCC被排除疗效分析(1位在初治组、1位在ICI治疗过组);因此,疗效分析共涵盖143位患者:初治组 22人、ICI初治组 17人、ICI治疗过组 104人。145位患者全部被纳入安全性分析。

各亚组的治疗缓解情况

中位随访了19.8个月(范围14.3-28.4)。24周时,初治组、ICI初治组和ICI治疗过组获得客观缓解的患者人数分别是16位(72.7%)、7位(41.2%)和58位(55.8%)。82位(57%)患者发生了3级治疗相关的不良事件,10位(7%)发生了4级治疗相关的不良事件。最常见的3级治疗相关不良事件为高血压(21%);发生了3例治疗相关死亡(上消化道出血、猝死和肺炎)。

既往接受过ICI治疗的患者采用乐伐替尼联合派姆单抗治疗的PFS和OS

综上所述,乐伐替尼联合派姆单抗在既往接受过ICI治疗的转移性RCC患者中表现出了令人鼓舞的抗肿瘤活性和可控的安全性,或可成为这类患者的新选择

原始出处:

Chung-Han Lee, et al. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. The Lancet Oncology. June 15, 2021. https://doi.org/10.1016/S1470-2045(21)00241-2

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1831211, encodeId=327f1831211e4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue May 31 20:54:01 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058145, encodeId=a268105814535, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8785526581, createdName=嗯嗯爱嗯嗯, createdTime=Wed Oct 06 16:56:19 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979151, encodeId=2c7e19e915178, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Jan 04 05:54:01 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866113, encodeId=cf0618661139a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Dec 12 18:54:01 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253474, encodeId=a3a712534e4d1, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65265, encryptionId=1c4e65265d5, topicName=派姆单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386776, encodeId=98941386e765c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420322, encodeId=84ba1420322cd, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93430, encryptionId=5ed393430f3, topicName=转移性肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da33575570, createdName=zhangyxzsh, createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025966, encodeId=d8ce10259662d, content=肿瘤免疫是大家关心的话题,K药与其它药对比,值得关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健康达人, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032965, encodeId=985e10329651b, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034360, encodeId=7836103436024, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=)]
    2022-05-31 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1831211, encodeId=327f1831211e4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue May 31 20:54:01 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058145, encodeId=a268105814535, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8785526581, createdName=嗯嗯爱嗯嗯, createdTime=Wed Oct 06 16:56:19 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979151, encodeId=2c7e19e915178, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Jan 04 05:54:01 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866113, encodeId=cf0618661139a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Dec 12 18:54:01 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253474, encodeId=a3a712534e4d1, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65265, encryptionId=1c4e65265d5, topicName=派姆单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386776, encodeId=98941386e765c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420322, encodeId=84ba1420322cd, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93430, encryptionId=5ed393430f3, topicName=转移性肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da33575570, createdName=zhangyxzsh, createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025966, encodeId=d8ce10259662d, content=肿瘤免疫是大家关心的话题,K药与其它药对比,值得关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健康达人, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032965, encodeId=985e10329651b, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034360, encodeId=7836103436024, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=)]
    2021-10-06 嗯嗯爱嗯嗯

    积分

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1831211, encodeId=327f1831211e4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue May 31 20:54:01 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058145, encodeId=a268105814535, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8785526581, createdName=嗯嗯爱嗯嗯, createdTime=Wed Oct 06 16:56:19 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979151, encodeId=2c7e19e915178, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Jan 04 05:54:01 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866113, encodeId=cf0618661139a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Dec 12 18:54:01 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253474, encodeId=a3a712534e4d1, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65265, encryptionId=1c4e65265d5, topicName=派姆单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386776, encodeId=98941386e765c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420322, encodeId=84ba1420322cd, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93430, encryptionId=5ed393430f3, topicName=转移性肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da33575570, createdName=zhangyxzsh, createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025966, encodeId=d8ce10259662d, content=肿瘤免疫是大家关心的话题,K药与其它药对比,值得关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健康达人, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032965, encodeId=985e10329651b, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034360, encodeId=7836103436024, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1831211, encodeId=327f1831211e4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue May 31 20:54:01 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058145, encodeId=a268105814535, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8785526581, createdName=嗯嗯爱嗯嗯, createdTime=Wed Oct 06 16:56:19 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979151, encodeId=2c7e19e915178, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Jan 04 05:54:01 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866113, encodeId=cf0618661139a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Dec 12 18:54:01 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253474, encodeId=a3a712534e4d1, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65265, encryptionId=1c4e65265d5, topicName=派姆单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386776, encodeId=98941386e765c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420322, encodeId=84ba1420322cd, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93430, encryptionId=5ed393430f3, topicName=转移性肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da33575570, createdName=zhangyxzsh, createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025966, encodeId=d8ce10259662d, content=肿瘤免疫是大家关心的话题,K药与其它药对比,值得关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健康达人, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032965, encodeId=985e10329651b, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034360, encodeId=7836103436024, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=)]
    2021-12-12 minlingfeng
  5. [GetPortalCommentsPageByObjectIdResponse(id=1831211, encodeId=327f1831211e4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue May 31 20:54:01 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058145, encodeId=a268105814535, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8785526581, createdName=嗯嗯爱嗯嗯, createdTime=Wed Oct 06 16:56:19 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979151, encodeId=2c7e19e915178, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Jan 04 05:54:01 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866113, encodeId=cf0618661139a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Dec 12 18:54:01 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253474, encodeId=a3a712534e4d1, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65265, encryptionId=1c4e65265d5, topicName=派姆单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386776, encodeId=98941386e765c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420322, encodeId=84ba1420322cd, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93430, encryptionId=5ed393430f3, topicName=转移性肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da33575570, createdName=zhangyxzsh, createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025966, encodeId=d8ce10259662d, content=肿瘤免疫是大家关心的话题,K药与其它药对比,值得关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健康达人, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032965, encodeId=985e10329651b, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034360, encodeId=7836103436024, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1831211, encodeId=327f1831211e4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue May 31 20:54:01 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058145, encodeId=a268105814535, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8785526581, createdName=嗯嗯爱嗯嗯, createdTime=Wed Oct 06 16:56:19 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979151, encodeId=2c7e19e915178, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Jan 04 05:54:01 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866113, encodeId=cf0618661139a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Dec 12 18:54:01 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253474, encodeId=a3a712534e4d1, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65265, encryptionId=1c4e65265d5, topicName=派姆单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386776, encodeId=98941386e765c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420322, encodeId=84ba1420322cd, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93430, encryptionId=5ed393430f3, topicName=转移性肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da33575570, createdName=zhangyxzsh, createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025966, encodeId=d8ce10259662d, content=肿瘤免疫是大家关心的话题,K药与其它药对比,值得关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健康达人, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032965, encodeId=985e10329651b, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034360, encodeId=7836103436024, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1831211, encodeId=327f1831211e4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue May 31 20:54:01 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058145, encodeId=a268105814535, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8785526581, createdName=嗯嗯爱嗯嗯, createdTime=Wed Oct 06 16:56:19 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979151, encodeId=2c7e19e915178, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Jan 04 05:54:01 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866113, encodeId=cf0618661139a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Dec 12 18:54:01 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253474, encodeId=a3a712534e4d1, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65265, encryptionId=1c4e65265d5, topicName=派姆单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386776, encodeId=98941386e765c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420322, encodeId=84ba1420322cd, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93430, encryptionId=5ed393430f3, topicName=转移性肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da33575570, createdName=zhangyxzsh, createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025966, encodeId=d8ce10259662d, content=肿瘤免疫是大家关心的话题,K药与其它药对比,值得关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健康达人, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032965, encodeId=985e10329651b, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034360, encodeId=7836103436024, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1831211, encodeId=327f1831211e4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue May 31 20:54:01 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058145, encodeId=a268105814535, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8785526581, createdName=嗯嗯爱嗯嗯, createdTime=Wed Oct 06 16:56:19 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979151, encodeId=2c7e19e915178, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Jan 04 05:54:01 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866113, encodeId=cf0618661139a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Dec 12 18:54:01 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253474, encodeId=a3a712534e4d1, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65265, encryptionId=1c4e65265d5, topicName=派姆单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386776, encodeId=98941386e765c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420322, encodeId=84ba1420322cd, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93430, encryptionId=5ed393430f3, topicName=转移性肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da33575570, createdName=zhangyxzsh, createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025966, encodeId=d8ce10259662d, content=肿瘤免疫是大家关心的话题,K药与其它药对比,值得关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健康达人, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032965, encodeId=985e10329651b, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034360, encodeId=7836103436024, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=)]
    2021-06-16 健康达人

    肿瘤免疫是大家关心的话题,K药与其它药对比,值得关注!

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1831211, encodeId=327f1831211e4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue May 31 20:54:01 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058145, encodeId=a268105814535, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8785526581, createdName=嗯嗯爱嗯嗯, createdTime=Wed Oct 06 16:56:19 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979151, encodeId=2c7e19e915178, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Jan 04 05:54:01 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866113, encodeId=cf0618661139a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Dec 12 18:54:01 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253474, encodeId=a3a712534e4d1, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65265, encryptionId=1c4e65265d5, topicName=派姆单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386776, encodeId=98941386e765c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420322, encodeId=84ba1420322cd, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93430, encryptionId=5ed393430f3, topicName=转移性肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da33575570, createdName=zhangyxzsh, createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025966, encodeId=d8ce10259662d, content=肿瘤免疫是大家关心的话题,K药与其它药对比,值得关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健康达人, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032965, encodeId=985e10329651b, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034360, encodeId=7836103436024, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=)]
    2021-06-16 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1831211, encodeId=327f1831211e4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue May 31 20:54:01 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058145, encodeId=a268105814535, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8785526581, createdName=嗯嗯爱嗯嗯, createdTime=Wed Oct 06 16:56:19 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979151, encodeId=2c7e19e915178, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Jan 04 05:54:01 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866113, encodeId=cf0618661139a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Dec 12 18:54:01 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253474, encodeId=a3a712534e4d1, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65265, encryptionId=1c4e65265d5, topicName=派姆单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386776, encodeId=98941386e765c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420322, encodeId=84ba1420322cd, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93430, encryptionId=5ed393430f3, topicName=转移性肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da33575570, createdName=zhangyxzsh, createdTime=Fri Jun 18 05:54:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025966, encodeId=d8ce10259662d, content=肿瘤免疫是大家关心的话题,K药与其它药对比,值得关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健康达人, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032965, encodeId=985e10329651b, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034360, encodeId=7836103436024, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Wed Jun 16 17:54:01 CST 2021, time=2021-06-16, status=1, ipAttribution=)]
    2021-06-16 goodbing

    顶刊就是不一样,质量很高,内容精彩!学到很多

    0

相关资讯

重磅!国内最佳治疗铂敏感及铂耐药复发性卵巢癌的PARP抑制剂帕米帕利获批

突破传统化疗局限,PARP抑制剂帕米帕利开启复发性卵巢癌治疗新时代!

Genet Med:PALB2和CHEK2 c.1100delC检测在乳腺-卵巢癌中的临床实用性

PALB2-PGV和CHEK2-1100delC总起来可解释约2.5%的家族性乳腺/卵巢癌风险

The Lancet:癌症早筛不能降低卵巢癌死亡率,癌症晚期患者将何去何从?

卵巢癌,70%的患者初诊时已是晚期、高达70%的复发率、50%-60%的患者在五年内死亡,一连串数字无一不在告诉我们卵巢癌的危险程度。这个被称为“沉默杀手”的毒瘤,与宫颈癌、子

Lancet Oncol:奥拉帕利长期维持治疗对患者生活质量的影响

在3期SOLO1试验中,奥拉帕利维持治疗为新确诊的携带BRCA突变的经以铂类为基础的化疗后获得缓解的晚期卵巢癌患者提供了相比安慰剂组明显延长的无进展生存期益处。

J Clin Oncol:晚期卵巢癌患者不宜采用免疫检查点抑制剂治疗!

据估计,2018年全球因OC死亡的人数接近18.5万